Vascular Disease

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

Published in Healthcare Finance, Tax and Law Weekly, November 21st, 2007

SCH 530348 (TRA), the novel investigational antiplatelet agent in development by Schering-Plough Corporation (NYSE:SGP), was shown to be a potent inhibitor of platelet aggregation in a sub-analysis of the Thrombin Receptor Antagonist - Percutaneous Coronary Intervention (TRA-PCI) trial presented today at the American Heart Association Scientific Sessions.

The pharmacokinetic and pharmacodynamic analysis, conducted by the University of Tennessee Health Science Center, Memphis, showed that SCH 530348 (TRA), a potent thrombin receptor antagonist, demonstrated sustained, dose- dependent, specific agonist-induced inhibition of platelet aggregation in blood samples from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry